Targeted therapy for breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer is classified into subtypes: hormone receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), and triple-negative.
• Targeted therapies against ER and HER2 are effective but face resistance challenges.
• Emerging research identifies novel therapeutic targets across breast cancer subtypes.

Purpose of the Study:

• To review current and developing targeted agents for breast cancer treatment.
• To discuss targeted therapies within the context of the three major clinical subgroups.
• To highlight the need for effective treatments for triple-negative breast cancer.

Main Methods:

• Literature review of targeted agents in breast cancer treatment.
• Analysis of clinical trial data for novel therapeutic pathways.
• Categorization of agents based on breast cancer subtype.

Main Results:

• Established targeted agents for ER(+) and HER2(+) breast cancer exist, with some facing resistance.
• Novel targets in PI3K/mTOR, cell-cycle, heat shock protein, and epigenetic pathways show promise.
• Everolimus (mTOR inhibitor) is approved for advanced ER(+) breast cancer resistant to aromatase inhibitors.
• No established targeted agents are currently available for triple-negative breast cancer.
• Poly(ADP-ribose) polymerase inhibitors show potential for BRCA-related cancers but require further study in triple-negative breast cancer.

Conclusions:

• Targeted therapies are revolutionizing breast cancer treatment by addressing specific molecular pathways.
• Continued research into novel targets and overcoming resistance is crucial for improving patient outcomes.
• Addressing the unmet need for effective treatments for triple-negative breast cancer remains a priority.